Subcutaneous Pembro vs IV in NSCLC

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy and safety profile with IV pembrolizumab.
Medscape Medical News

source https://www.medscape.com/viewarticle/subcutaneous-pembro-par-iv-administration-lung-cancer-2025a10007lc?src=rss